Does Transcatheter Closure of Patent Foramen Ovale Really “Shut the Door?”
- 1 September 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 35 (9) , 2140-2144
- https://doi.org/10.1161/01.str.0000137764.07815.de
Abstract
Background and Purpose— Transcatheter closure of patent foramen ovale (PFO) is increasingly being performed and monitored with transthoracic or transesophageal echocardiography, whereas contrast-enhanced transcranial Doppler (ce-TCD), which probably represents the most suitable tool to quantify right-to-left shunt (RLS) in the brain vessels, has been systematically overlooked. Our goal is to prospectively assess efficacy and safety of PFO transcatheter closure using ce-TCD. Methods— A total of 140 consecutive patients (mean age, 46±13 years; male/female ratio, 63/77) with PFO-related large RLS and no other recognized cause of focal cerebral ischemia underwent transcatheter closure. TCD was done preoperatively and 1 month after the procedure in all patients, after 3 months in 120, after 6 months in 112, and after 1 year in 104 patients. Results— Implantation was successful in all patients. During Valsalva strain, a large shunt was still detectable in 31 of 140 (22%), 15 of 120 (13%), 9 of 112 (8%), and 9 of 104 (9%) patients at the 1-, 3-, 6-, and 12-month visits, respectively. Periprocedural and postprocedural complications included atrial fibrillation in 8% and scintillating scotomata in 6% of patients. During the 1-year follow-up period, only 1 transient ischemic attack was recorded in a patient with paroxysmal atrial fibrillation and complete PFO closure. Conclusions— Transcatheter PFO closure in patients with cryptogenic stroke and large RLS may be less successful than reported previously. TCD appears the ideal tool to follow up the closure process and to identify early, during follow-up, those patients who will be left with a significant shunt. Atrial fibrillation is more common than believed previously and may underlie the occurrence of further cerebrovascular events despite complete PFO closure. Irritative visual phenomena may occur as a consequence of nickel toxicity.Keywords
This publication has 18 references indexed in Scilit:
- Five-year clinical and echocardiographic evaluation of the Das AngelWings atrial septal occluderAmerican Heart Journal, 2004
- Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacyHeart, 2004
- Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical EmbolismMayo Clinic Proceedings, 2004
- Nickel release after implantation of the Amplatzer occluderAmerican Heart Journal, 2003
- Percutaneous Transcatheter Closure of Patent Foramen Ovale in Patients With Paradoxical EmbolismCirculation, 2002
- Transcatheter Closure of Interatrial Communications for Secondary Prevention of Paradoxical EmbolismCirculation, 2002
- Effect of Medical Treatment in Stroke Patients With Patent Foramen OvaleCirculation, 2002
- Outcome of patients with cryptogenic stroke and patent foramen ovaleJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale, Atrial Septal Aneurysm, or BothNew England Journal of Medicine, 2001
- Transcatheter closure of atrial septal defect and patent foramen ovale with the ASDOS device (a multi-institutional European trial)The American Journal of Cardiology, 1998